← Back to Screener
Neurocrine Biosciences Inc (NBIX)
Price$161.00
Value ScoreC
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-2.03%
Price vs S&P 500 (4W)15.15%
VGM Score62.41
Market Capitalization$15.92B
P/E Ratio (Annual)33.26x
All Metrics
P/CF (Annual)20.34x
Book Value / Share (Quarterly)$33.87
P/TBV (Annual)5.41x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)24.32%
Cash Flow / Share (Quarterly)$8.26
Price vs S&P 500 (YTD)0.68%
Gross Margin (TTM)98.17%
Net Profit Margin (TTM)21.55%
EPS (TTM)$6.50
10-Day Avg Trading Volume1.15M
EPS Excl Extra (TTM)$6.50
Revenue Growth (5Y)22.29%
EPS (Annual)$4.67
ROI (Annual)14.71%
Gross Margin (Annual)98.18%
Net Profit Margin (5Y Avg)12.55%
Cash / Share (Quarterly)$13.08
P/E Basic Excl Extra (TTM)23.81x
Revenue Growth QoQ (YoY)42.25%
EPS Growth (5Y)2.31%
P/E Normalized (Annual)33.26x
ROA (Last FY)10.33%
Revenue Growth TTM (YoY)28.59%
EBITD / Share (TTM)$7.94
ROE (5Y Avg)10.93%
Operating Margin (TTM)25.43%
Cash Flow / Share (Annual)$7.48
P/B Ratio4.67x
P/B Ratio (Quarterly)3.89x
Net Income / Employee (Annual)$239,300
EV / Revenue (TTM)5.04x
Net Interest Coverage (TTM)6.75x
ROA (TTM)15.12%
EPS Growth QoQ (YoY)2382.36%
EV / EBITDA (TTM)19.19x
EPS Incl Extra (Annual)$4.67
Current Ratio (Annual)3.39x
Quick Ratio (Quarterly)2.58x
3-Month Avg Trading Volume1.17M
52-Week Price Return28.01%
EV / Free Cash Flow (Annual)20.90x
P/E Incl Extra (TTM)23.81x
Revenue / Employee (TTM)$1,551,200
Tangible BV / Share (Quarterly)$29.77
P/S Ratio (Annual)5.56x
Asset Turnover (Annual)0.62x
52-Week High$162.39
Operating Margin (5Y Avg)16.04%
EPS Excl Extra (Annual)$4.67
CapEx CAGR (5Y)25.55%
Tangible BV CAGR (5Y)73.41%
26-Week Price Return13.90%
Quick Ratio (Annual)3.07x
13-Week Price Return21.17%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.93x
Enterprise Value$15.65B
Revenue / Share Growth (5Y)21.15%
Asset Turnover (TTM)0.70x
Book Value / Share Growth (5Y)21.96%
Revenue / Employee (Annual)$1,430,300
Inventory Turnover (Annual)0.82x
Pretax Margin (Annual)24.66%
Cash / Share (Annual)$14.79
3-Month Return Std Dev29.85%
Gross Margin (5Y Avg)98.36%
Net Income / Employee (TTM)$334,300
EBITDA CAGR (5Y)33.31%
EBITDA Interim CAGR (5Y)42.62%
ROE (Last FY)14.71%
Net Interest Coverage (Annual)3.03x
EPS Basic Excl Extra (Annual)$4.67
P/FCF (TTM)19.15x
Receivables Turnover (TTM)4.83x
EV / Free Cash Flow (TTM)18.83x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$6.50
Receivables Turnover (Annual)4.91x
ROI (TTM)21.64%
P/S Ratio (TTM)5.13x
Pretax Margin (5Y Avg)17.24%
Revenue / Share (Annual)$27.91
Tangible BV / Share (Annual)$25.69
Forward P/E20.30x
Free OCF CAGR (5Y)28.04%
Price vs S&P 500 (52W)-0.19%
P/E Ratio (TTM)23.81x
EPS Growth TTM (YoY)120.33%
Year-to-Date Return11.61%
5-Day Price Return1.02%
EPS Normalized (Annual)$4.67
ROA (5Y Avg)7.61%
Net Profit Margin (Annual)16.73%
Month-to-Date Return20.22%
Cash Flow / Share (TTM)$2.11
EBITD / Share (Annual)$6.29
EPS Growth (3Y)44.05%
Operating Margin (Annual)21.64%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)18.43x
ROI (5Y Avg)10.35%
P/E Excl Extra (TTM)23.81x
LT Debt / Equity (Quarterly)0.10x
EPS Basic Excl Extra (TTM)$6.50
P/TBV (Quarterly)4.69x
P/B Ratio (Annual)4.35x
Inventory Turnover (TTM)0.92x
Pretax Margin (TTM)30.22%
Book Value / Share (Annual)$32.50
Price vs S&P 500 (13W)11.43%
Net Margin Growth (5Y)-15.55%
Beta0.40x
P/FCF (Annual)21.26x
Revenue / Share (TTM)$30.00
ROE (TTM)21.64%
52-Week Low$121.42
vGradeC
gGradeB
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 261.91est. 1.18
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.20
4.22
4.22
4.23
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
| TECHBio-Techne Corp. | D | C | C | $50.79 |
About
Neurocrine Biosciences develops and commercializes pharmaceutical treatments for neurological, psychiatric, endocrine, and immunological disorders. Key marketed products address tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids, while a pipeline of candidates spans multiple therapeutic modalities including small molecules, peptides, proteins, antibodies, and gene therapies. The company generates revenue from pharmaceutical product sales.